Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.
Grisham R, Monk BJ, Van Nieuwenhuysen E, Moore KN, Fabbro M, O'Malley DM, Oaknin A, Thaker P, Oza AM, Colombo N, Gershenson D, Aghajanian CA, Choi CH, Lee YC, Mirza MR, Coleman RL, Cobb L, Harter P, Lustgarten S, Youssoufian H, Banerjee S. Grisham R, et al. Among authors: monk bj. Int J Gynecol Cancer. 2024 Oct 7:ijgc-2024-005919. doi: 10.1136/ijgc-2024-005919. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39375168
Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG. Thigpen JT, et al. Among authors: monk bj. Gynecol Oncol. 2005 Jan;96(1):10-8. doi: 10.1016/j.ygyno.2004.09.046. Gynecol Oncol. 2005. PMID: 15589573 Review.
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gómez J, Park YC, Alfaro V, Monk BJ. Poveda A, et al. Among authors: monk bj. Ann Oncol. 2011 Jan;22(1):39-48. doi: 10.1093/annonc/mdq352. Epub 2010 Jul 19. Ann Oncol. 2011. PMID: 20643862 Free PMC article. Clinical Trial.
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
Kaye SB, Colombo N, Monk BJ, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Vergote I, Lebedinsky C, Parekh T, Santabárbara P, Park YC, Nieto A, Poveda A. Kaye SB, et al. Among authors: monk bj. Ann Oncol. 2011 Jan;22(1):49-58. doi: 10.1093/annonc/mdq353. Epub 2010 Jul 19. Ann Oncol. 2011. PMID: 20643863 Free PMC article. Clinical Trial.
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD. Herzog TJ, et al. Among authors: monk bj. Gynecol Oncol. 2014 Jan;132(1):8-17. doi: 10.1016/j.ygyno.2013.11.008. Epub 2013 Nov 15. Gynecol Oncol. 2014. PMID: 24239753 Free PMC article.
Improved survival with bevacizumab in advanced cervical cancer.
Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Tewari KS, et al. Among authors: monk bj. N Engl J Med. 2014 Feb 20;370(8):734-43. doi: 10.1056/NEJMoa1309748. N Engl J Med. 2014. PMID: 24552320 Free PMC article. Clinical Trial.
452 results